Worth Watching: ImmunoCellular Therapeutics Ltd’s Stock Is Sell After Today’s Huge Decline

Worth Watching: ImmunoCellular Therapeutics Ltd's Stock Is Sell After Today's Huge Decline

The stock of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is a huge mover today! The stock decreased 10.03% or $0.32 on November 23, hitting $2.87. About 90,624 shares traded hands or 89.98% up from the average. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) has declined 73.24% since April 22, 2016 and is downtrending. It has underperformed by 78.65% the S&P500.
The move comes after 7 months negative chart setup for the $9.56 million company. It was reported on Nov, 24 by Barchart.com. We have $2.70 PT which if reached, will make NYSEMKT:IMUC worth $573,600 less.

Analysts await ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) to report earnings on March, 29. They expect $-1.60 EPS, up 33.33% or $0.80 from last year’s $-2.4 per share. After $-1.60 actual EPS reported by ImmunoCellular Therapeutics Ltd for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

According to Zacks Investment Research, “ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.”

Insitutional Activity: The institutional sentiment decreased to 0.67 in 2016 Q2. Its down 0.58, from 1.25 in 2016Q1. The ratio worsened, as 2 funds sold all ImmunoCellular Therapeutics Ltd shares owned while 6 reduced positions. 2 funds bought stakes while 8 increased positions. They now own 12.21 million shares or 0.10% less from 12.23 million shares in 2016Q1.
Bank Of America De holds 0% or 1,085 shares in its portfolio. Nomura holds 0% or 22,170 shares in its portfolio. Moreover, Northern Trust has 0% invested in ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) for 83,704 shares. State Street last reported 29,173 shares in the company. California Employees Retirement Systems holds 0% or 209,100 shares in its portfolio. Creative Planning holds 4,000 shares or 0% of its portfolio. Retail Bank Of New York Mellon Corporation reported 124,881 shares or 0% of all its holdings. The California-based Bailard Incorporated has invested 0.06% in ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC). Raymond James Associates holds 0% or 15,200 shares in its portfolio. Morgan Stanley last reported 0% of its portfolio in the stock. Kcg reported 45,898 shares or 0% of all its holdings. The New York-based Cowen Gp Incorporated has invested 0% in ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC). Commonwealth Equity Svcs accumulated 0% or 27,000 shares. Moreover, Financial Architects has 0% invested in ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) for 42 shares. Citadel Lc owns 42,042 shares or 0% of their US portfolio.

Another recent and important ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) news was published by Prnewswire.com which published an article titled: “ImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split” on November 16, 2016.

IMUC Company Profile

ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Firm is developing immune therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. The Company’s product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. The Company’s other product candidates are ICT-140 for ovarian cancer and ICT-121 for recurrent glioblastoma multiforme (GBM).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment